Successful management of intractable cryptosporidial diarrhea with intravenous octreotide, a somatostatin analogue. 1991

G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

A 38-year-old man with AIDS and intractable large-volume diarrhea due to a cryptosporidial infection was successfully treated with intravenous octreotide, a somatostatin analogue. The volume of diarrhea, 10-12 liters with 8-13 movements per day, was reduced to three to four semi-formed to formed stools per day when the patient was treated with 400 micrograms intravenous octreotide daily. The patient's intravenous hyperalimentation was discontinued and he returned to oral feeding. He quickly regained his normal weight and has now resumed his normal activities. For those patients who cannot tolerate subcutaneous administration, intravenous octreotide therapy may not only be life-saving but may also markedly increase the quality of life. Roxithromycin, a macrolide antibiotic, was also administered to this patient with cryptosporidiosis but efficacy was not demonstrated.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D003457 Cryptosporidiosis Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA. Cryptosporidium Infection,Cryptosporidioses,Cryptosporidium Infections,Infection, Cryptosporidium
D003967 Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. Diarrheas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995
D015575 Roxithromycin Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections. Biaxsig,Claramid,Infectoroxit,MTW-Roxithromycin,Macrosil,RU 28965,RU 965,RU-28965,RU-965,Rotesan,Rotramin,Roxi 1A Pharma,Roxi Basics,Roxi TAD,Roxi-Puren,Roxi-Q,Roxi-Wolff,Roxi-paed 1A Pharma,Roxi-saar,Roxibeta,Roxigamma,Roxigrün,Roxihexal,Roxithro-Lich,Rulid,Rulide,roxi von ct,roxidura,RU28965,RU965

Related Publications

G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
June 1999, Endocrine journal,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
August 1994, Archives of internal medicine,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
April 1994, Presse medicale (Paris, France : 1983),
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
October 2001, Nihon rinsho. Japanese journal of clinical medicine,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
April 1989, Clinical pharmacy,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
June 1994, Deutsche medizinische Wochenschrift (1946),
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
January 1995, Acta crystallographica. Section D, Biological crystallography,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
December 2009, Current medical research and opinion,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
September 2007, No to hattatsu = Brain and development,
G Kreinik, and O Burstein, and M Landor, and L Bernstein, and L M Weiss, and M Wittner
April 1989, Annals of internal medicine,
Copied contents to your clipboard!